Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
复制标题

DOI:
10.1177/1352458520937282
复制
发表时间:
2021-05
期刊:
Multiple sclerosis (Houndmills, Basingstoke, England)
影响因子:
--
通讯作者:
Robertson D
Robertson D
中科院分区:
其他
文献类型:
--
作者:
Longbrake EE;Mao-Draayer Y;Cascione M;Zielinski T;Bame E;Brassat D;Chen C;Kapadia S;Mendoza JP;Miller C;Parks B;Xing D;Robertson D

文献摘要

参考文献

被引文献

相似文献

Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially, then stabilizes on treatment. PROCLAIM, a 96-week, prospective, open-label, phase 3b study, assessed lymphocyte subsets and immunoglobulin (Ig) levels during 48 and 96 weeks (W) of DMF treatment. Patients received 240 mg DMF BID. Endpoints: lymphocyte subset count changes (primary); Ig isotypes and ALC changes (secondary); adverse events and relationship between ALC changes and ARR/EDSS (exploratory); and neurofilament assessment (ad hoc). Of 218 patients enrolled, 158 (72%) completed the study. Median ALC decreased 39% from baseline to W96 (BL–W96), stabilizing above the lower limit of normal (baseline: 1.82 × 109/L; W48: 1.06 × 109/L; W96: 1.05 × 109/L). CD4 + and CD8 + T cells correlated highly with ALC from BL–W96 (p < 0.001). Relative to total T cells, naive CD4 + and CD8 + T cells increased, whereas CD4 + and CD8 + central and effector memory T cells decreased. Total IgA, IgG, IgM, and IgG1–4 subclass levels remained stable. Adverse event rates were similar across ALC subgroups. ARR, EDSS, and neurofilament were not correlated with ALCs. Lymphocyte decreases with DMF were maintained over treatment, yet immunoglobulins remained stable. No increase in infection incidence was observed in patients with or without lymphopenia. Biogen
DOI: 10.1177/1352458517707069
发表时间: 2018-05-01
影响因子: 5.8
作者:
Longbrake, Erin E.;Cantoni, Claudia;Piccio, Laura
通讯作者: Piccio, Laura
DOI: 10.1212/wnl.0000000000007262
发表时间: 2019-04-09
期刊: NEUROLOGY
影响因子: 9.9
作者:
Mehta, Devangi;Miller, Catherine;Fox, Robert J.
通讯作者: Fox, Robert J.
DOI: 10.1084/jem.20100977
发表时间: 2011-10-24
期刊: The Journal of experimental medicine
影响因子: --
作者:
Ghoreschi K;Brück J;Kellerer C;Deng C;Peng H;Rothfuss O;Hussain RZ;Gocke AR;Respa A;Glocova I;Valtcheva N;Alexander E;Feil S;Feil R;Schulze-Osthoff K;Rupec RA;Lovett-Racke AE;Dringen R;Racke MK;Röcken M
通讯作者: Röcken M
DOI: 10.3389/fimmu.2016.00450
发表时间: 2016
影响因子: 7.3
作者:
Kennedy RB;Ovsyannikova IG;Haralambieva IH;Oberg AL;Zimmermann MT;Grill DE;Poland GA
通讯作者: Poland GA
DOI: 10.1038/s41467-019-11139-3
发表时间: 2019-07-12
影响因子: 16.6
作者:
Carlstrom, Karl E.;Ewing, Ewoud;Piehl, Fredrik
通讯作者: Piehl, Fredrik